LRMR - Larimar Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
3.89 0.38 (9.77%)	---	0.0 (0.0%)	0.0 (0.0%)	0.1 (2.57%)	0.34 (8.67%)	-0.03 (-0.7%)	-0.03 (-0.7%)

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.41
Diluted EPS:: -0.41
Basic P/E:: -10.4146
Diluted P/E:: -10.4146
RSI(14) 1m:: 0.0
VWAP:: 4.27
RVol:: 0.3215

Events

Period	Kind	Movement	Occurred At
Day	Price increase day	4.38 +0.49 (+12.47%)	Oct 15 16:17
1m	Price increase 1m	4.16 +0.09 (+2.34%)	Oct 15 13:21
1m	Price increase 1m	3.97 +0.05 (+1.28%)	Oct 15 09:31